Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Concurrent Adjuvant Chemoradiation in High-Risk Breast Cancer
NCT05288777Phase 3Recruiting
- Sponsor
- University of Virginia
- Start
- Jul 2022
- Primary completion
- Dec 2028
- Modality
- Monoclonal Antibodies, DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors
- Countries
- 1
01
Overview
Phase 3, open-label trial of trastuzumab emtansine and capecitabine in breast cancer (4 arms), sponsored by University of Virginia. Primary endpoints: Safety via toxicity grading at 1 year and Feasibility via treatment delays and completion at 1 year. Started Jul 2022; status: recruiting.
02
Drugs
trastuzumab emtansinecapecitabine
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05288777.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05288777.